Tricida Inc - TCDA

Tricida Inc (TCDA) is a biopharmaceutical company that is primarily focused on developing treatments for chronic kidney disease (CKD). The company's lead product candidate is veverimer, a non-absorbed, orally administered polymer designed to treat metabolic acidosis in CKD patients. Metabolic acidosis is a common complication of CKD that can lead to adverse health outcomes such as bone disease, muscle wasting, and the progression of CKD itself. Veverimer works by binding and removing excess acid in the gastrointestinal tract, thus addressing the underlying cause of metabolic acidosis.

Tricida has completed a Phase 3 clinical trial of veverimer, called the TRCA-301 trial, which evaluated the safety and efficacy of the drug in CKD patients with metabolic acidosis. The trial met its primary endpoint, demonstrating statistically significant improvement in the proportion of patients with serum bicarbonate levels greater than or equal to 22 mEq/L at week 52 compared to placebo. The company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for veverimer and is awaiting a decision.

In addition to veverimer, Tricida is also developing a pipeline of product candidates for the treatment of various other conditions associated with CKD, such as inflammation and fibrosis.

LIQD QLTA TECTP RM TMDI AVAV ALKS ZIM DLPN APSA CPLA INO